Abstract 221: Prognostic Role of elevated Myeloperoxidase in Patients with Acute Coronary Syndrome: A Systemic Review and Meta-Analysis.

2014 ◽  
Vol 115 (suppl_1) ◽  
Author(s):  
Andrew R Kolodziej ◽  
Charles L Campbell ◽  
Richard Charnigo ◽  
Raphael Twerenbold ◽  
Christian Mueller ◽  
...  
Keyword(s):  
Acute Coronary Syndrome ◽  
Meta Analysis ◽  
Systemic Review ◽  
Major Adverse Cardiovascular Events ◽  
Poor Prognostic Factor ◽  
Coronary Syndrome ◽  
Prospective Trials ◽  
Long Term Prognosis

BACKGROUND: It has been shown that Myeloperoxidase (MPO) is intimately involved in pathogenesis of atherosclerosis and Acute Coronary Syndrome (ACS). Small studies have shown that high levels of MPO are a poor prognostic factor in patients presenting with ACS. However, due to the small nature of these studies, the relationship between MPO and outcomes has not been confirmed. Here we aimed to examine the prognostic value of MPO in patients with ACS. METHODS: We performed a meta-analysis to compare the long-term prognosis of ACS patients with high MPO and low MPO levels. The literature was retrieved by formal searches of electronic databases (PubMed, EMBASE, Medline, OVID, and web of knowledge) from inception to November 2013. A total of 16 trials were included in this meta-analysis involving 10572 patients. Data were analyzed using random-effects model and study quality was assessed using appropriate scales. RESULTS: High MPO group was associated with overall worse outcomes than low MPO group in terms of recurrent myocardial infarction (9% [211 of 2336] vs. 7.7% [240 of 3101], odds ratio [OR] 1.4, 95% confidence interval [CI]: 0.92-2.15, p 0.11); all cause mortality (8% [236 of 2920] vs. 5% [209 of 4263], OR 1.83, 95% CI: 1.31-2.54, p <0.0004) and Major Adverse Cardiovascular Events (MACE) (24% [334 of 1400] vs. 14% [133 of 949], OR 2.04, 95% CI: 1.46-2.85, p< 0.0001) (Figure). CONCLUSIONS: In this meta-analysis examining the long-term outcomes in ACS patients, high MPO levels were associated with worse outcomes. These observations support prospective trials tailoring more aggressive therapy to patients with suspected worse prognosis.

Long-Term Risk of Major Adverse Cardiovascular Events in Patients With Acute Coronary Syndrome: Prognostic Role of Complete Blood Cell Count

Angiology ◽  
2020 ◽  
Vol 71 (9) ◽  
pp. 831-839
Author(s):  
Nuccia Morici ◽  
Valentina Molinari ◽  
Silvia Cantoni ◽  
Andrea Rubboli ◽  
Laura Antolini ◽  
...  
Keyword(s):  
Acute Coronary Syndrome ◽  
High Risk ◽  
Blood Cell ◽  
Cardiovascular Events ◽  
Major Adverse Cardiovascular Events ◽  
Blood Cell Count ◽  
Prognostic Role ◽  
Coronary Syndrome

Individual parameters of complete blood count (CBC) have been associated with worse outcome in patients with acute coronary syndrome (ACS). However, the prognostic role of CBC taken as a whole has never been evaluated for long-term incidence of major adverse cardiovascular events (MACEs). Patients were grouped according to their hematopoietic cells’ inflammatory response at different time points during hospital stay. Patients with admission white blood cell count >10 × 109/L, discharge hemoglobin <120 g/L, and discharge platelet count >250 × 109/L were defined as “high-risk CBC.” Among 1076 patients with ACS discharged alive, 129 (12%) had a “high-risk CBC” and 947 (88%) had a “low-risk CBC.” Patients with “high-risk CBC” were older and had more comorbidities. Over a median follow-up of 665 days, they experienced a higher incidence of MACE compared to “low-risk CBC” patients (18.6% vs 8.1%). After adjustment for age, age-adjusted Charlson comorbidity index, female sex, cardiac arrest, suboptimal discharge therapy, coronary artery bypass, and ejection fraction, a high-risk CBC was significantly associated with increased MACE occurrence (adjusted hazard ratio 1.80; 95% CI: 1.09-3.00). The CBC was a prognostic marker in patients with ACS, and its evaluation at admission and discharge could better classify patient’s risk and improve therapeutic management.

scholarly journals Predictive role of platelet indices on hospital admission and discharge in the long-term prognosis of acute coronary syndrome: Platelets do count

2021 ◽  
Vol 28 (Supplement_1) ◽  
Author(s):  
G Psarakis ◽  
I Farmakis ◽  
S Zafeiropoulos ◽  
C Tsolakidis ◽  
O Konstantas ◽  
...  
Keyword(s):  
Acute Coronary Syndrome ◽  
Regression Analysis ◽  
Cox Regression ◽  
Minor Bleeding ◽  
Cox Regression Analysis ◽  
Platelet Indices ◽  
Coronary Syndrome ◽  
Long Term Prognosis

Abstract Funding Acknowledgements Type of funding sources: None. Background/Introduction: Previous clinical studies have underlined the prognostic role of platelet indices in acute coronary syndrome (ACS). However, the effect of their dynamic change during hospitalization has not thoroughly been examined. Purpose: We aimed to investigate the association between platelet indices on admission, on discharge and their change during hospitalization and the long-term prognosis of patients with ACS. Methods: Data from a randomized controlled trial recruiting ACS patients were analyzed in a survival analysis. Platelet count (PC), mean platelet volume (MPV), platelet distribution width (PDW) and plateletcrit (PCT) on admission and on discharge dichotomized at the median value, as well as the change between admission and discharge of each variable dichotomized at the zero value. Primary endpoints were major adverse cardiac events (MACE), defined as occurrence of cardiovascular death, non-fatal myocardial infarction, non-fatal stroke or hospitalization for unstable angina, while secondary endpoints were all-cause mortality, all-cause hospitalization and major or minor bleeding events. Results: The study included 252 individuals who were followed-up for a median of 39 months. In the univariate Cox regression analysis, only PC at discharge (HR 2.20, 95% CI 1.10-4.40), MPV at discharge (HR 0.48, 95% CI 0.25-0.94) and PC reduction during the hospitalization (HR 0.25, 95% CI 0.13-0.51) predicted MACE. PC reduction correlated with a lower MACE occurrence (adjusted HR 0.27, 95%CI 0.14-0.54) and lower risk of all-cause hospitalization (adjusted HR 0.36, 95%CI 0.19-0.68) in the multivariable Cox-regression analysis. Conclusion: PC change during hospitalization can be a substantial independent predictor of long-term prognosis of ACS patients. Baseline and admission characteristics Characteristic Statistic Overall, N = 252 Negative Platelet Difference, N = 98 Postive Platelet Difference, N = 154 p-value Age, years median (IQR) 60 (53, 72) 62 (55, 74) 60 (53, 72) 0.2 Hypertension n(%) 147(58.3%) 58(59.2%) 89(57.8%) &gt;0.9 Diabetes n(%) 71(28.2%) 27(27.6%) 44(28.6%) &gt;0.9 Cardiovascualr Disease (CVD) n(%) 100(39.7%) 43(43.9%) 57(37.0%) 0.3 Primary Coronary Intervention (PCI) treatment n(%) 200(79.4%) 71(72.4%) 129(83.8%) 0.045 Number of vessels n 0.6 1 n(%) 107(59.1%) 38(59.4%) 69(59.0%) ≥2 n(%) 68(37.6%) 25(39.1%) 43(36.8%) Platelets at admission, K/μL mean(SD) 257179(71031) 237020(62555) 270006(73282) 0.001 Platelets at dischage, K/μL mean(SD) 250952(70263) 279153(75159) 233006(60698) &lt;0.001 Abstract Figure. MACE univariate / multivariate analysis

scholarly journals Prognostic Role of Elevated Myeloperoxidase in Patients with Acute Coronary Syndrome: A Systemic Review and Meta-Analysis

2019 ◽  
Vol 2019 ◽  
pp. 1-9 ◽  
Author(s):  
Andrew R. Kolodziej ◽  
Mohamed Abo-Aly ◽  
Eman Elsawalhy ◽  
Charles Campbell ◽  
Khaled M. Ziada ◽  
...  
Keyword(s):  
Acute Coronary Syndrome ◽  
Clinical Outcomes ◽  
Prognostic Value ◽  
Meta Analysis ◽  
Sensitivity Analyses ◽  
Systemic Review ◽  
Myocardial Inflammation ◽  
Prognostic Role ◽  
Coronary Syndrome

Background. Myocardial inflammation following acute ischemic injury has been linked to poor cardiac remodeling and heart failure. Many studies have linked myeloperoxidase (MPO), a neutrophil and inflammatory marker, to cardiac inflammation in the setting of acute coronary syndrome (ACS). However, the prognostic role of MPO for adverse clinical outcomes in ACS patients has not been well established. Methods. MEDLINE and Cochrane databases were searched for studies from 1975 to March 2018 that investigated the prognostic value of serum MPO in ACS patients. Studies which have dichotomized patients into a high MPO group and a low MPO group reported clinical outcomes accordingly and followed up patients for at least 30 days to be eligible for enrollment. Data were analyzed using random-effects model. Sensitivity analyses were conducted for quality control. Results. Our meta-analysis included 13 studies with 9090 subjects and a median follow-up of 11.4 months. High MPO level significantly predicted mortality (odds ratio (OR) 2.03; 95% confidence interval (CI): 1.40-2.94; P<0.001), whereas it was not significantly predictive of major adverse cardiac events and recurrent myocardial infarction (MI) (OR 1.28; CI: 0.92-1.77, P=0.14 and OR 1.23; CI: 0.96-1.58, P=0.101, respectively). Hypertension, diabetes mellitus, and age did not affect the prognostic value of MPO for clinical outcomes, whereas female gender and smoking status have a strong influence on the prognostic value of MPO in terms of mortality and recurrent MI (metaregression coefficient -8.616: 95% CI -14.59 to -2.633, P=0.0048 and 4.88: 95% CI 0.756 to 9.0133, P=0.0204, respectively). Conclusions. Our meta-analysis suggests that high MPO levels are associated with the risk of mortality and that MPO can be incorporated in risk stratification models that guide therapy of high-risk ACS patients.

Abstract 1715: Prognosis of Patients Under Chronic Clopidogrel Therapy while Suffering an Acute Coronary Syndrome

Circulation ◽  
2008 ◽  
Vol 118 (suppl_18) ◽  
Author(s):  
Laurent Bonello ◽  
Axel de Labriolle ◽  
Gilles Lemesle ◽  
Probal Roy ◽  
Daniel H Steinberg ◽  
...  
Keyword(s):  
Acute Coronary Syndrome ◽  
Cardiac Death ◽  
Major Adverse Cardiovascular Events ◽  
Coronary Syndrome ◽  
Clopidogrel Therapy ◽  
Artery Disease ◽  
Long Term Prognosis ◽  
Worse Prognosis

Background: Chronic clopidogrel therapy (CCT) has been shown to be beneficial in decreasing the frequency of major adverse cardiovascular events (MACE) in coronary artery disease. However, some patients suffer an acute coronary syndrome (ACS) despite CCT. Objective : To assess the prognosis of patients suffering an ACS while on CCT compared to patients naive to clopidogrel. Method: Retrospective analysis of propensity matched cohorts of patients undergoing PCI for an ACS was performed. Patients under CCT before the ACS were matched 1:2 with patients not under CCT before the ACS. The primary endpoint was a composite of cardiac death and myocardial infarction (MI) at 1-year follow-up. A cohort of 2325 patients undergoing PCI for an ACS was studied. Among them, 256 patients were taking CCT for > 1 month at the time of the ACS and 2069 weren’t taking clopidogrel prior to the ACS. After propensity score matching 1:2, the 2 groups included, respectively, 84 and 168 patients. Results: Patients in both groups had similar rates of previous MI (no CCT vs CCT 47.6 vs 48.8%; p = 0.86) or PCI (40.5 vs 40.5%; p = 1). There was no difference in drug use on discharge between the 2 groups; in particular for thienopyridines (94 vs 96.4%; p = 0.6). At 1-year follow-up, patients under CCT before the ACS exhibited a worse prognosis than patients who were not under CCT prior to the ACS, with a higher rate of cardiac death and MI (14.2 vs 5.5%; p = 0.015). Conclusions: This study suggests that patients suffering an ACS while under CCT have a poor long-term prognosis, which could be linked to clopidogrel low response.

Sign in / Sign up

Export Citation Format

Share Document